Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2016

01-02-2016 | Original Article

Association of cancer stem cell markers genetic variants with gallbladder cancer susceptibility, prognosis, and survival

Authors: Anu Yadav, Annapurna Gupta, Neeraj Rastogi, Sushma Agrawal, Ashok Kumar, Vijay Kumar, Balraj Mittal

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

Genes important to stem cell progression have been involved in the genetics and clinical outcome of cancers. We investigated germ line variants in cancer stem cell (CSC) genes to predict susceptibility and efficacy of chemoradiotherapy treatment in gallbladder cancer (GBC) patients. In this study, we assessed the effect of SNPs in CSC genes (surface markers CD44, ALCAM, EpCAM, CD133) and (molecular markers NANOG, SOX-2, LIN-28A, ALDH1A1, OCT-4) with GBC susceptibility and prognosis. Total 610 GBC patients and 250 controls were genotyped by using PCR-RFLP, ARMS-PCR, and TaqMan allelic discrimination assays. Chemotoxicity graded 2–4 in 200 patients and tumor response was recorded in 140 patients undergoing neoadjuvant chemotherapy (NACT). Differences in genotype and haplotype frequency distributions were calculated by binary logistic regression. Gene-gene interaction model was analyzed by generalized multifactor dimensionality reduction (GMDR). Overall survival was assessed by Kaplan-Meier survival curve and multivariate Cox-proportional methods. ALCAM Ars1157Crs10511244 (P = 0.0035) haplotype was significantly associated with GBC susceptibility. In GMDR analysis, ALCAM rs1157G>A, EpCAM rs1126497T>C emerged as best significant interaction model with GBC susceptibility and ALDH1A1 rs13959T>G with increased risk of grade 3–4 hematological toxicity. SOX-2 rs11915160A>C, OCT-4 rs3130932T>G, and NANOG rs11055786T>C were found best gene-gene interaction model for predicting response to NACT. In both Cox-proportional and recursive partitioning ALCAM rs1157GA+AA genotype showed higher mortality and hazard ratio. ALCAM gene polymorphisms associated with GBC susceptibility and survival while OCT-4, SOX-2, and NANOG variants showed an interactive role with treatment response.
Appendix
Available only for authorised users
Literature
1.
Rebecca Siegel MJM, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 2014;64:29.
2.
Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4:167–76.CrossRefPubMed
3.
Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea—a paradigm shift. Cancer Res. 2006;66:1883–90. discussion 1895-1886.CrossRefPubMed
4.
Bourguignon LY, Singleton PA, Zhu H, Diedrich F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem. 2003;278:29420–34.CrossRefPubMed
5.
Bourguignon LY. CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia. 2001;6:287–97.CrossRefPubMed
6.
Baumann M, Krause M. CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy. Clin Cancer Res. 2010;16:5091–3.CrossRefPubMed
7.
Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, et al. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther. 2010;10:1182–90.CrossRefPubMed
8.
Sharma KL, Yadav A, Gupta A, Tulsayan S, Kumar V, Misra S, et al. Association of genetic variants of cancer stem cell gene CD44 haplotypes with gallbladder cancer susceptibility in North Indian population. Tumour Biol. 2014;35:2583–9.CrossRefPubMed
9.
Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med. 1995;181:2213–20.CrossRefPubMed
10.
Burandt E, Bari Noubar T, Lebeau A, Minner S, Burdelski C, Janicke F, et al. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients. Oncol Rep. 2014;32:2628–34.PubMed
11.
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1012–24.CrossRefPubMed
12.
Imrich S, Hachmeister M, Gires O. EpCAM and its potential role in tumor-initiating cells. Cell Adhes Migr. 2012;6:30–8.CrossRef
13.
Pereira F, Rosenmann E, Nylen E, Kaufman M, Pinsky L, Wrogemann K. The 56 kDa androgen binding protein is an aldehyde dehydrogenase. Biochem Biophys Res Commun. 1991;175:831–8.CrossRefPubMed
14.
Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B, Ng HH, et al. Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem. 2005;280:24731–7.CrossRefPubMed
15.
16.
Chou YE, Hsieh MJ, Chiou HL, Lee HL, Yang SF, Chen TY. CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features. Biomed Res Int. 2014;2014:231474.PubMedPubMedCentral
17.
Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011;17:6934–43.CrossRefPubMed
18.
Wang Q, Liu H, Xiong H, Liu Z, Wang LE, Qian J, et al. Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Mol Carcinog. 2015;54:449–58.CrossRefPubMed
19.
20.
Lou XY, Chen GB, Yan L, Ma JZ, Zhu J, Elston RC, et al. A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet. 2007;80:1125–37.CrossRefPubMedPubMedCentral
21.
22.
Jiang Y, Qin Z, Hu Z, Guan X, Wang Y, He Y, et al. Genetic variation in a hsa-let-7 binding site in RAD52 is associated with breast cancer susceptibility. Carcinogenesis. 2013;34:689–93.CrossRefPubMed
23.
Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57:327–34.CrossRefPubMed
24.
Winder T, Ning Y, Yang D, Zhang W, Power DG, Bohanes P, et al. Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. Int J Cancer. 2011;129:1096–104.CrossRefPubMedPubMedCentral
25.
Chou YE, Hsieh MJ, Hsin CH, Chiang WL, Lai YC, Lee YH, et al. CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in taiwan. PLoS One. 2014;9:e93692.CrossRefPubMedPubMedCentral
26.
Roa I, Villaseca M, Araya J, Roa J, de Aretxabala X, Ibacache G, et al. CD44 (HCAM) expression in subserous gallbladder carcinoma. Rev Med Chil. 2001;129:727–34.PubMed
27.
Yanagisawa N, Mikami T, Mitomi H, Saegusa M, Koike M, Okayasu I. CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation. Cancer. 2001;91:408–16.CrossRefPubMed
28.
Jiang L, Zhang C, Li Y, Yu X, Zheng J, Zou P, et al. A non-synonymous polymorphism Thr115Met in the EpCAM gene is associated with an increased risk of breast cancer in Chinese population. Breast Cancer Res Treat. 2011;126:487–95.CrossRefPubMed
29.
Katafigiotis S, Papamichos SI, Katopodi R, Papazisis K, Mylonaki E, Repana D, et al. A case-control study on the rs3130932 single nucleotide polymorphism in the OCT4B translation initiation codon in association with cancer state. Eur J Cancer Prev. 2011;20:248–51.CrossRefPubMed
30.
Qiu C, Ma Y, Wang J, Peng S, Huang Y. Lin28-mediated post-transcriptional regulation of Oct4 expression in human embryonic stem cells. Nucleic Acids Res. 2010;38:1240–8.CrossRefPubMed
31.
Tulsyan S, Agarwal G, Lal P, Mittal B. Significant association of combination of OCT4, NANOG, and SOX2 gene polymorphisms in susceptibility and response to treatment in North Indian breast cancer patients. Cancer Chemother Pharmacol. 2014;74:1065–78.CrossRefPubMed
32.
Szkandera J, Herzog S, Pichler M, Stiegelbauer V, Stotz M, Schaberl-Moser R, et al. Lgr5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy. Pharmacogenomics J. 2015.
33.
Situ D, Long H, Lin P, Zhu Z, Wang J, Zhang X, et al. Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin Oncol. 2010;136:1213–9.CrossRefPubMed
34.
Stoll C, Baretton G, Soost F, Terpe HJ, Domide P, Lohrs U. Prognostic importance of the expression of CD44 splice variants in oral squamous cell carcinomas. Oral Oncol. 1999;35:484–9.CrossRefPubMed
35.
Yang Y, Fei F, Song Y, Li X, Zhang Z, Fei Z, et al. Polymorphisms of EpCAM gene and prognosis for non-small-cell lung cancer in Han Chinese. Cancer Sci. 2014;105:89–96.CrossRefPubMed
36.
Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, et al. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG phase III trial S0221 for breast cancer. Pharmacogenomics J. 2014;14:241–7.CrossRefPubMed
37.
Varadi V, Bevier M, Grzybowska E, Johansson R, Enquist-Olsson K, Henriksson R, et al. Genetic variation in ALCAM and other chromosomal instability genes in breast cancer survival. Breast Cancer Res Treat. 2012;131:311–9.CrossRefPubMed
38.
Jiang L, Deng J, Zhu X, Zheng J, You Y, Li N, et al. Cd44 rs13347 c>t polymorphism predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Res. 2012;14:R105.CrossRefPubMedPubMedCentral
Metadata
Title
Association of cancer stem cell markers genetic variants with gallbladder cancer susceptibility, prognosis, and survival
Authors
Anu Yadav
Annapurna Gupta
Neeraj Rastogi
Sushma Agrawal
Ashok Kumar
Vijay Kumar
Balraj Mittal
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3929-6

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue

Original Article

FXR1 is elevated in colorectal cancer and acts as an oncogene

Review

The immunobiology of myeloid-derived suppressor cells in cancer

Original Article

G648C variant of DNA polymerase β sensitizes esophageal cancer to chemotherapy

Original Article

Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib

Original Article

Upregulated expression of long non-coding RNA LINC00982 regulates cell proliferation and its clinical relevance in patients with gastric cancer

Erratum

Erratum to: Promyelocytic leukemia protein enhances apoptosis of gastric cancer cells through Yes-associated protein
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits